Consider rifampin BUT be cautious.
Joanne Y Julien
Elena S Hollender
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
Non-rifampin rifamycins in TB
Richard E. Chaisson + 4 • Aug 15, 2017
Clinical Trial Simulations of Effectiveness of Reduced-Dose Efavirenz Therapy: Impact of adherence, pharmacogenetics and rifampin co-administration
John Fors + 3 • Nov 02, 2017